Impact of genetic polymorphism of SDF1 3A on efficacy of captopril in Chinese patients with essential hypertension.
OBJECTIVE
To explore the association of SDF1 3A genetic polymorphism with susceptibility of essential hypertension and captopril efficacy in patients with essential hypertension.


METHODS
A total of 214 patients with essential hypertension and 228 healthy controls were genotyped for SDF1 3A polymorphism by polymerase chain reaction-restriction fragment length polymorphism assay. Among 39 subjects with different SDF1 3A of genotypes, 13 hypertensive patients simultaneously took oral captopril (25 mg/d) and nitrendipine (30 mg/d), and 12 patients orally received nitrendipine alone for 8 consecutive weeks, and 14 healthy controls did not take any agents. The blood pressure of all subjects was measured to evaluate the therapeutic efficacy.


RESULTS
There was a significant difference in the plasma SDF-1 level in individuals with AA+AG genotypes or GG genotypes of SDF1 3A treated with nitrendipine plus captopril compared with healthy control (P < 0.05). Carriers with AA genotypes of SDF1 3A had lower total protein and globulin than those with GG genotypes (P < 0.05). After captopril treatment, hypertensive patients with AA+AG genotypes had bigger attenuated systolic blood pressure compared with those with GG genotypes (P < 0.05).


CONCLUSIONS
Genetic polymorphism of SDF1 3A could influence the therapeutic efficacy of captopril in Chinese hypertensive patients.
Yan
Yan
Y
Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China.
Ning
Chen
C
Zhou
Huan
H
Yang
Xiheng
X
Yang
Tianlun
T
Liu
Zhaoqian
Z
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001483:Base Sequence; D002216:Captopril / Q000627:therapeutic use*; D016022:Case-Control Studies; D054377:Chemokine CXCL12 / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D012150:Polymorphism, Restriction Fragment Length
D000959:Antihypertensive Agents; D054377:Chemokine CXCL12; D002216:Captopril